Phase IV Postmarketing Surveillance Study Shows Continued Efficacy and Safety of Stempeucel in Patients with Critical Limb Ischemia Due to Buerger's Disease
Open Access
- 13 September 2021
- journal article
- research article
- Published by Oxford University Press (OUP) in Stem Cells Translational Medicine
- Vol. 10 (12) , 1602-1613
Abstract
Buerger's disease or thromboangiitis obliterans is a type of obstructive vascular diseases categorized as vasculitis and usually present in 95% of young smoker men. The main pathogenetic mechanism is interplay between immune system and inflammation. Earlier our phase II study has shown that Stempeucel is safe when injected at 2 million cells/kg body weight by virtue of its anti-inflammatory, immunomodulatory, and angiogenetic properties. The present study was conducted to further assess the safety and efficacy of Stempeucel in critical limb ischemia due to Buerger's disease after obtaining approval from Indian FDA based on the data generated in the phase II study. This is an open label, multicenteric phase IV PMS study conducted across India with experienced vascular surgeons. Fifty patients of critical limb ischemia due to Buerger's disease with Rutherford III-5 or III-6 were included in the study and each individual received a dose of 2 million cells/kg body weight of Stempeucel in the calf muscles and around the ulcer. These patients were evaluated over 12 months from drug administration. The present study showed the continued long term efficacy over a period of 12 months follow up in these patients corroborating the result obtained in the previous phase II studies. There was significant improvement in rest pain, ankle systolic pressure, and ankle brachial pressure index with accelerated ulcer healing. In conclusion, the present study shows that the intramuscular administration of Stempeucel continues to be safe, tolerable, and effective alternative treatment in patients with Buerger's disease.Keywords
This publication has 39 references indexed in Scilit:
- A double blind randomized placebo controlled phase I/II study assessing the safety and efficacy of allogeneic bone marrow derived mesenchymal stem cell in critical limb ischemiaJournal of Translational Medicine, 2013
- Safety of Cell Therapy with Mesenchymal Stromal Cells (SafeCell): A Systematic Review and Meta-Analysis of Clinical TrialsPLOS ONE, 2012
- Harnessing the Mesenchymal Stem Cell Secretome for the Treatment of Cardiovascular DiseaseCell Stem Cell, 2012
- Effect of fibroblast growth factor NV1FGF on amputation and death: a randomised placebo-controlled trial of gene therapy in critical limb ischaemiaThe Lancet, 2011
- Thromboangiitis ObliteransCirculation, 2010
- A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study of Intravenous Adult Human Mesenchymal Stem Cells (Prochymal) After Acute Myocardial InfarctionJACC, 2009
- Bone marrow–derived mesenchymal stem cells facilitate engineering of long-lasting functional vasculatureBlood, 2008
- Mesenchymal Stem Cells Enhance Wound Healing Through Differentiation and AngiogenesisStem Cells, 2007
- Thromboangiitis obliterans or Buerger's disease: challenges for the rheumatologistRheumatology, 2006
- Long-term survival and amputation risk in thromboangiitis obliterans (Buerger's disease)JACC, 2004